COGNITION THERAPEUTICS INC. - COMMON STOCK

0,4106

10-марта-25 16:45:00

15 мин. задержка

Акции

-0,0180

-4,20%

Сегодняшний диапазон

0,4031 - 0,4397

ISIN

N/A

Источник

NASDAQ

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

10 мар 2025 07:30:44 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

27 фев 2025 07:30:08 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy

26 фев 2025 07:00:00 Источник Nasdaq GlobeNewswire
Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

25 фев 2025 07:30:40 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)

20 фев 2025 07:30:00 Источник Nasdaq GlobeNewswire
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

30 янв 2025 07:30:33 Источник Nasdaq GlobeNewswire
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

08 янв 2025 16:14:32 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

18 дек 2024 07:22:43 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

26 ноя 2024 07:30:22 Источник Nasdaq GlobeNewswire
Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population

25 ноя 2024 07:30:49 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

13 ноя 2024 07:30:45 Источник Nasdaq GlobeNewswire
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

12 ноя 2024 07:30:38 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

31 окт 2024 16:15:00 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

29 окт 2024 12:55:00 Источник Nasdaq GlobeNewswire
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD

23 окт 2024 07:30:27 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

22 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

02 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

01 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

03 сен 2024 07:30:00 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease

22 авг 2024 07:31:24 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.